HOME >> BIOLOGY >> NEWS
Effective Alzheimer treatment: The nose knows

Alzheimer disease (AD) is the most common form of senile dementia, with no effective treatment available. In a study appearing online on August 11 in advance of print publication of the September 1 issue of the Journal of Clinical Investigation, Howard Weiner and colleagues from Harvard describe a novel immunologic approach for the treatment of AD.

Previous studies utilizing immunization against Abeta, a key pathogenic player in AD, to generate antibodies against Abeta were discontinued because of unacceptable side effects in AD patients.

Here, the researchers use a specific nasal vaccination to decrease AD burden in mice. The vaccine consists of an FDA-approved drug currently used to treat multiple sclerosis (called glatiramer acetate) plus a recently developed nasal adjuvant that has been shown to be safe in humans and activates microglia, cells which then clear beta-amyloid in the brain without evidence of toxic effects.

The findings have both basic and clinically relevant implications. The discovery of a non-antibody mediated method to clear Abeta could be used as a treatment for patients who already are showing signs of AD. Moreover, the compounds used have already been safely tested in humans.


'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
11-Aug-2005


Page: 1

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Effective new biodiversity data access portal
3. PET/CT use expands: Effectively diagnosing graft infections
4. Effectiveness of certain antidepressants may be influenced by gene variations of individuals
5. UCF, NIH study: Effective, safe anthrax vaccine can be grown in tobacco plants
6. Effective cancer treatments follow the clock
7. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
8. Link identified between Alzheimers disease and glaucoma
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Journal of Alzheimers Disease achieves significant impact factor
11. Alzheimers prevention role discovered for prions

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Effective Alzheimer treatment The nose knows

(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
Cached News: